Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by stanleyon Feb 13, 2013 9:25am
293 Views
Post# 20980253

Talking About Synergies wrt BRD & SAS

Talking About Synergies wrt BRD & SAS

Talking About Possible Synergies:

  • A combination of the Hislop and Grey Fox mine would almost certainly show some impressive economics beating the two stand-alone scenarios hands down.

[S] <both in the same downfaulted block ... as the past producing Ross Mine>> to me it explains the delay in bring Grey Fox into production as the benefit of this contiguity (cannot use closeology, due to venemous objections to my use of closeology but parties not in favour of free speech).

  • St. Andrew Goldfield's Taylor mine is situated next door to Brigus Gold's existing mill, while St. Andrew Goldfield's mill is 80km away.
  • Brigus Gold's own Black Fox mine is situated only four kilometers from the Grey Fox project.

Are the two management teams talking to each other trying to find ways to exploit these potential synergies in the interest of both companies? Shareholders would presumably very much hope so!

With St. Andrew Goldfields working towards bringing the Taylor mine online and Brigus Gold working on the feasibility study of the Grey Fox mine a window of opportunity might be opening up for both companies and astute investors.

 

------------------------------See details in link below ---------------

BWDIK??? Remember SAS "took a run" at APG .......

https://seekingalpha.com/article/1175661-a-window-of-opportunity-for-2-canadian-mid-cap-gold-miners?source=yahoo

 

 

Bullboard Posts